Volume : 09, Issue : 03, March – 2021
13.A BRIEF OVERVIEW ON LIVER CIRRHOSIS
Shilpa L.S*, Merlin N.J, Shaiju. S. Dharan
Abstract :
Cirrhosis is a complication of liver disease and leading cause of morbidity and mortality around the world. Chronic liver diseases represent a crucial health problem across the globe with liver cirrhosis. It is characterized by the formation of regenerative nodules in liver parenchyma enclosed by fibrous septa and loss of liver cells and irreversible scarring of the liver because of chronic liver injury. Cirrhosis of liver always occurs due to necrosis of liver cells followed by fatty liver and fibrosis. The liver structure becomes abnormal and involved with liver blood flow and perform that leads to portal hypertension, Hepatic encephalopathy and impaired hepatocytes performance. Chronic liver diseases represent a crucial health problem across the globe with liver cirrhosis. However, treatment of cirrhosis is designed to prevent further damage to the liver, treat complications of cirrhosis the recent advances within the identification, diagnosis and treatment of chronic liver diseases have changed the treatment history of cirrhosis significantly. Diagnosis of cirrhosis based how badly your liver is injured that includes serological test, and radio techniques like ultrasonography, and magnetic resonance imaging. Ursodeoxycholic acid has anti-apoptotic action that is used for treatment of primary biliary cirrhosis. Silymarin (Silybum marianum) acts as a free radical scavenger, reduces the inflammatory reaction and also modulates enzymes associated with the development of cellular damage, fibrosis and cirrhosis.
Keywords: Liver cirrhosis, Complications, multiple cell types, Radio Techniques, Ursodeoxycholic acid and Silymarin.
Cite This Article:
Please cite this article in press Shilpa L.S et al., A Brief Overview On Liver Cirrhosis., Indo Am. J. P. Sci, 2021; 08(03).
Number of Downloads : 10
References:
2. Hayat Ouassou, Mohamed Bouhrim, Nour Elhouda Daoudi, Hassane Mekhfi, Abderrahim Ziyyat.Evaluation of Hepatoprotective Activity of Caralluma europaea Stem Extract against CCl4-Induced Hepatic Damage in Wistar Rats. Advances in Pharmacological and Pharmaceutical Sciences, 2021. 8883040.
3. Manoj Suva. A Brief Review on Liver Cirrhosis: Epidemiology, Etiology, Pathophysiology, Symptoms, Diagnosis and Its Management. Inventi Rapid: Molecular Pharmacology 2014(2): 1-5.
4. Valeer J. Desmet, Tania Roskams . Cirrhosis reversal: a duel between dogma and myth. Journal of Hepatology.2004 (40), 860–867.
5. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008 Mar 8;371(9615):838-51.
6. Salman Nusrat, Muhammad S Khan, Javid Fazili, Mohammad F Madhoun. Cirrhosis and its complications: Evidence based treatment. World J Gastroenterol 2014 May 14; 20(18): 5442-5460
7. Qi, X., Arora, A., Tang, S., Mancuso, A., & Romeiro, F. G. Prognostic Assessment and Management of Liver Cirrhosis. BioMed Research International, 2017, 1–3.
8. Werner M, Driftmann S, Kleinehr K, Kaiser GM, Mathé Z, Treckmann J-W, All-In-One: Advanced preparation of Human Parenchymal and Non-Parenchymal Liver Cells. PLoS ONE .2015,10(9): e0138655.
9. Xing Wang and Bin Wu.Critical issues in the diagnosis and treatment of liver cirrhosis. Gastroenterology Report, 7(4), 2019, 227–230.
10. Wen-Ce Zhou, Quan-Bao Zhang, Liang Qiao. Pathogenesis of liver cirrhosis. World Journal Gastroenterol 2014 June 21; 20(23): 7312-7324.
11. Ki Tae Suk, Dong Joon Kim. Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement. World Journal Hepatol 2015 March 27; 7(3): 607-615.
12. Bei Li, Chuan Zhang , and Yu-Tao Zhan. Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. J Gastroenterol Hepatol. 2018,8 pages 2784537
13. Wiegand J, Berg T. The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Dtsch Arztebl Int. 2013 Feb;110(6):85-91.
14. Zohair Ahmed, Umair Ahmed,and Sonu Dhillon.Liver function tests in identifying patients with liver disease. Clin Exp Gastroenterol. 2018; 11: 301–307.
15. 10 Zardi EM, Caturelli E. May sonography distinguish between liver fibrosis and liver steatosis. Dig Liver Dis 2007; 39: 790
16. Kudo M, Zheng RQ, Kim SR, Okabe Y, Osaki Y, Iijima H, Itani T, Kasugai H, Kanematsu M, Ito K, Usuki N, Shimamatsu K, Kage M, Kojiro M. Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. A multicenter collaborative study. Intervirology 2008; 51 Suppl 1: 17-26
17. Varenika V, Fu Y, Maher JJ, Gao D, Kakar S, Cabarrus MC, Yeh BM. Hepatic fibrosis: evaluation with semiquantitative contrastenhanced CT. Radiology 2013; 266: 151-158
18. Maurizio Soresi, Lydia Giannitrapani, Melchiorre Cervello. Non invasive tools for the diagnosis of liver cirrhosis. World J Gastroenterol 2014 December 28; 20(48): 18131-18150.
19. Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liver fibrosis: noninvasive diagnosis with double contrast materialenhanced MR imaging. Radiology 2006; 239: 425-437.
20. Magd A. Kotb. Molecular Mechanisms of Ursodeoxycholic Acid Toxicity & Side Effects: Ursodeoxycholic Acid Freezes Regeneration & Induces Hibernation Mode. International Journal of Molecular Sciences. 2012, 13, 8882-8914.
21. Ding, T.; Tian, S.; Zhang, Z.; Gu, D.; Chen, Y.; Shi, Y.; Sun, Z. Determination of active components in silymarin by RP-LC and LC/MS. J. Pharm. Biomed. Anal. 2001, 26, 155–161.
22. Lu, C.; Lu, Y.; Chen, J.; Zhang, W.; Wu, W. Synchronized and sustained release of multiple components in silymarin from erodible glyceryl monostearate matrix system. Eur. J. Pharm. Biopharm. 2007, 66, 210–219.
23. M.Trauner & I.W. Graziadei. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 1999; 13: 979-995.
24. Zun Xiang , Yi-peng Chen , Kui-fen Ma. The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterology 2013, 13:140
25. Nancy Vargas, Eduardo Madrigal, Angel Morales. Hepatoprotective effect of silymarin. World Journal Hepatology 2014 March 27; 6(3): 144-149.
26. Iaizzo, P.A.; Laske, T.G.; Harlow, H.J.; McClay, C.B.; Garshelis, D.L. Wound healing during hibernation by black bears (Ursus americanus) in the wild: Elicitation of reduced scar formation. Integr. Zool. 2012, 7, 48–60.
27. Kwon DY, Jung YS, Kim SJ, Kim YS, Choi DW, Kim YC. Alterations in sulfur amino acid metabolism in mice treated with silymarin: a novel mechanism of its action involved in enhancement of the antioxidant defense in liver. Planta Med. 2013;79(12):997–1002.
28. Anton Gillessen. Hartmut H.-J. Schmidt. Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. Adv Ther. 2020 Apr;37(4):1279-1301.